新型冠状病毒治疗药物。
COVID-19 therapeutics.
机构信息
North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy.
Division of Hematology and Transfusion Medicine, Carlo Poma Hospital, Mantua, Italy.
出版信息
Clin Microbiol Rev. 2024 Jun 13;37(2):e0011923. doi: 10.1128/cmr.00119-23. Epub 2024 May 21.
Abstract
SUMMARYSince the emergence of COVID-19 in 2020, an unprecedented range of therapeutic options has been studied and deployed. Healthcare providers have multiple treatment approaches to choose from, but efficacy of those approaches often remains controversial or compromised by viral evolution. Uncertainties still persist regarding the best therapies for high-risk patients, and the drug pipeline is suffering fatigue and shortage of funding. In this article, we review the antiviral activity, mechanism of action, pharmacokinetics, and safety of COVID-19 antiviral therapies. Additionally, we summarize the evidence from randomized controlled trials on efficacy and safety of the various COVID-19 antivirals and discuss unmet needs which should be addressed.
摘要
摘要自 2020 年 COVID-19 出现以来，已经研究并部署了前所未有的治疗方案范围。医疗保健提供者有多种治疗方法可供选择，但这些方法的疗效往往存在争议或因病毒进化而受到影响。对于高危患者，最佳治疗方法仍存在不确定性，并且药物研发管道因资金短缺而面临疲劳。在本文中，我们回顾了 COVID-19 抗病毒治疗的抗病毒活性、作用机制、药代动力学和安全性。此外，我们总结了随机对照试验中关于各种 COVID-19 抗病毒药物疗效和安全性的证据，并讨论了需要解决的未满足需求。
相似文献
1
COVID-19 therapeutics.新型冠状病毒治疗药物。
Clin Microbiol Rev. 2024 Jun 13;37(2):e0011923. doi: 10.1128/cmr.00119-23. Epub 2024 May 21.
2
Convalescent plasma may be a possible treatment for COVID-19: A systematic review.恢复期血浆可能是治疗 COVID-19 的一种方法：系统评价。
Int Immunopharmacol. 2021 Feb;91:107262. doi: 10.1016/j.intimp.2020.107262. Epub 2020 Dec 5.
4
Potential therapeutic options for COVID-19: an update on current evidence.针对 COVID-19 的潜在治疗选择：当前证据的更新。
Eur J Med Res. 2022 Jan 13;27(1):6. doi: 10.1186/s40001-021-00626-3.
5
Current Therapeutics for COVID-19, What We Know about the Molecular Mechanism and Efficacy of Treatments for This Novel Virus.新型冠状病毒肺炎的治疗现状：对该新型病毒治疗方法的分子机制和疗效的了解。
Int J Mol Sci. 2022 Jul 12;23(14):7702. doi: 10.3390/ijms23147702.
6
Emerging treatment strategies for COVID-19 infection.针对 COVID-19 感染的新兴治疗策略。
Clin Exp Med. 2021 May;21(2):167-179. doi: 10.1007/s10238-020-00671-y. Epub 2020 Oct 30.
7
Perspective on the Role of Antibodies and Potential Therapeutic Drugs to Combat COVID-19.对抗 COVID-19 中抗体和潜在治疗性药物作用的思考。
Protein J. 2020 Dec;39(6):631-643. doi: 10.1007/s10930-020-09921-0. Epub 2020 Oct 9.
8
Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit.美国国立卫生研究院 SARS-CoV-2 抗病毒治疗峰会报告。
J Infect Dis. 2021 Jul 15;224(Supplement_1):S1-S21. doi: 10.1093/infdis/jiab305.
9
Transformative approaches in SARS-CoV-2 management: Vaccines, therapeutics and future direction.SARS-CoV-2管理中的变革性方法：疫苗、治疗方法及未来方向。
Virology. 2025 Mar;604:110394. doi: 10.1016/j.virol.2025.110394. Epub 2025 Jan 10.
10
Antiviral combination therapies for persistent COVID-19 in immunocompromised patients.免疫功能低下患者持续性 COVID-19 的抗病毒联合疗法。
Int J Infect Dis. 2023 Dec;137:55-59. doi: 10.1016/j.ijid.2023.09.021. Epub 2023 Sep 30.
引用本文的文献
1
Cardiovascular Safety of COVID-19 Treatments: A Disproportionality Analysis of Adverse Event Reports from the WHO VigiBase.新型冠状病毒肺炎治疗的心血管安全性：来自世界卫生组织药物不良反应数据库不良事件报告的不成比例性分析
Infect Dis Ther. 2025 Sep 11. doi: 10.1007/s40121-025-01225-z.
2
Computational Evaluation and Multi-Criteria Optimization of Natural Compound Analogs Targeting SARS-CoV-2 Proteases.针对新型冠状病毒蛋白酶的天然化合物类似物的计算评估与多标准优化
Curr Issues Mol Biol. 2025 Jul 21;47(7):577. doi: 10.3390/cimb47070577.
3
In Vitro Investigation of Statin Effects on Genes Associated with Severe COVID-19 in Cancerous and Non-Cancerous Cells.他汀类药物对癌细胞和非癌细胞中与重症 COVID-19 相关基因影响的体外研究
Biomedicines. 2025 Jul 14;13(7):1714. doi: 10.3390/biomedicines13071714.
4
Concurrent Fulminant Myocarditis and Severe Rhabdomyolysis in COVID-19-related Multisystem Inflammatory Syndrome in Adults: A Case Report and Review of the Literature.成人新冠病毒相关多系统炎症综合征并发暴发性心肌炎和严重横纹肌溶解症：一例报告及文献复习
Intern Med. 2025;64(13):2007-2013. doi: 10.2169/internalmedicine.5068-24. Epub 2025 Jul 1.
5
Synthetic host defense peptide inhibits SARS-CoV-2 replication .合成宿主防御肽可抑制新型冠状病毒复制。
Antimicrob Agents Chemother. 2025 Jun 23:e0170024. doi: 10.1128/aac.01700-24.
6
COVID-19 Vaccination in Patients with Hematological Malignances.血液系统恶性肿瘤患者的新冠病毒疫苗接种
Vaccines (Basel). 2025 Apr 25;13(5):465. doi: 10.3390/vaccines13050465.
7
Naive and Memory B Cell BCR Repertoires in Individuals Immunized with an Inactivated SARS-CoV-2 Vaccine.接种灭活新冠病毒疫苗个体中的初始B细胞和记忆B细胞BCR库
Vaccines (Basel). 2025 Apr 8;13(4):393. doi: 10.3390/vaccines13040393.
8
The Antiviral Effect of Ephedrine Alkaloids-Free Ephedra Herb Extract, EFE, on Murine Coronavirus Growth in the Lung and Liver of Infected Mice.不含麻黄碱生物碱的麻黄草提取物（EFE）对感染小鼠肺和肝中鼠冠状病毒生长的抗病毒作用。
Microorganisms. 2025 Apr 6;13(4):830. doi: 10.3390/microorganisms13040830.
9
Angiotensin-converting enzyme 2 and hepatic SARS-CoV-2 infection: Regulation, association, and therapeutic implications.血管紧张素转换酶2与肝脏严重急性呼吸综合征冠状病毒2感染：调控、关联及治疗意义
World J Gastroenterol. 2025 Feb 14;31(6):100864. doi: 10.3748/wjg.v31.i6.100864.
10
SARS-CoV-2 Evolution: Implications for Diagnosis, Treatment, Vaccine Effectiveness and Development.严重急性呼吸综合征冠状病毒2的进化：对诊断、治疗、疫苗有效性及研发的影响
Vaccines (Basel). 2024 Dec 28;13(1):17. doi: 10.3390/vaccines13010017.
本文引用的文献
1
Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in NHS hospitals in England.在英格兰国民保健服务体系（NHS）医院中，推测接受索托维单抗治疗的新冠病毒疾病（COVID-19）患者的特征及治疗结果
BMC Infect Dis. 2024 Apr 22;24(1):428. doi: 10.1186/s12879-024-09311-2.
2
Genetic consequences of effective and suboptimal dosing with mutagenic drugs in a hamster model of SARS-CoV-2 infection.在新冠病毒（SARS-CoV-2）感染的仓鼠模型中，使用致突变药物进行有效和次优剂量给药的遗传后果。
Virus Evol. 2024 Jan 4;10(1):veae001. doi: 10.1093/ve/veae001. eCollection 2024.
3
Remdesivir for COVID-19 in Hospitalized Children: A Phase 2/3 Study.瑞德西韦治疗住院儿童 COVID-19：一项 2/3 期研究。
Pediatrics. 2024 Mar 1;153(3). doi: 10.1542/peds.2023-063775.
4
Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19.莫努匹拉韦或安慰剂用于新冠肺炎住院患者的随机试验
NEJM Evid. 2022 Feb;1(2):EVIDoa2100044. doi: 10.1056/EVIDoa2100044. Epub 2021 Dec 16.
5
Safety of COVID-19 convalescent plasma: A definitive systematic review and meta-analysis of randomized controlled trials.新冠康复者血浆的安全性：一项关于随机对照试验的确定性系统评价和荟萃分析。
Transfusion. 2024 Feb;64(2):388-399. doi: 10.1111/trf.17701. Epub 2023 Dec 29.
6
Is antiviral treatment at the acute phase of COVID-19 effective for decreasing the risk of long-COVID? A systematic review.COVID-19 急性期中的抗病毒治疗是否能降低长新冠的风险？一项系统综述。
Infection. 2024 Feb;52(1):43-58. doi: 10.1007/s15010-023-02154-0. Epub 2023 Dec 19.
7
Outpatient randomized controlled trials to reduce COVID-19 hospitalization: Systematic review and meta-analysis.减少 COVID-19 住院的门诊随机对照试验：系统评价和荟萃分析。
J Med Virol. 2023 Dec;95(12):e29310. doi: 10.1002/jmv.29310.
8
Cost-Effectiveness of Oral Nirmatrelvir/Ritonavir in Patients at High Risk for Progression to Severe COVID-19 in the United States.口服奈玛特韦/利托那韦在有进展为重症 COVID-19 高风险的美国患者中的成本效益。
Value Health. 2024 Feb;27(2):164-172. doi: 10.1016/j.jval.2023.11.003. Epub 2023 Dec 2.
9
Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study.中国轻至中度 COVID-19 患者中口服 VV116 与安慰剂对照的多中心、双盲、3 期、随机对照研究。
Lancet Infect Dis. 2024 Feb;24(2):129-139. doi: 10.1016/S1473-3099(23)00577-7. Epub 2023 Nov 22.
10
Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial.巴瑞替尼或瑞维鲁单抗治疗成人重症 COVID-19 患者的疗效和安全性（TACTIC-R）：一项随机、平行臂、开放标签、四期临床试验。
Lancet Respir Med. 2023 Dec;11(12):1064-1074. doi: 10.1016/S2213-2600(23)00376-4. Epub 2023 Nov 14.
Zotero 插件